Home >> Research Area >>Cancer Biology>>Cancer Biology Peptides>> Fas C- Terminal Tripeptide

Fas C- Terminal Tripeptide

AC-SER-LEU-VAL-OH CAS# 189109-90-8

Fas C- Terminal Tripeptide

Catalog No. BCC1019----Order now to get a substantial discount!

Product Name & Size Price Stock
Fas C- Terminal Tripeptide: 5mg $334 In Stock
Fas C- Terminal Tripeptide: 10mg Please Inquire In Stock
Fas C- Terminal Tripeptide: 20mg Please Inquire Please Inquire
Fas C- Terminal Tripeptide: 50mg Please Inquire Please Inquire
Fas C- Terminal Tripeptide: 100mg Please Inquire Please Inquire
Fas C- Terminal Tripeptide: 200mg Please Inquire Please Inquire
Fas C- Terminal Tripeptide: 500mg Please Inquire Please Inquire
Fas C- Terminal Tripeptide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Fas C- Terminal Tripeptide

Number of papers citing our products

Chemical structure

Fas C- Terminal Tripeptide

3D structure

Chemical Properties of Fas C- Terminal Tripeptide

Cas No. 189109-90-8 SDF Download SDF
PubChem ID 9209375 Appearance Powder
Formula C16H29N3O6 M.Wt 359.42
Type of Compound N/A Storage Desiccate at -20°C
Synonyms Ac-Ser-Leu-Val-OH
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Sequence Ac-Ser-Leu-Val-OH
Chemical Name (2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-methylbutanoic acid
SMILES CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)C(CO)NC(=O)C
Standard InChIKey ORIIRLCDJGETQD-AVGNSLFASA-N
Standard InChI InChI=1S/C16H29N3O6/c1-8(2)6-11(14(22)19-13(9(3)4)16(24)25)18-15(23)12(7-20)17-10(5)21/h8-9,11-13,20H,6-7H2,1-5H3,(H,17,21)(H,18,23)(H,19,22)(H,24,25)/t11-,12-,13-/m0/s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Fas C- Terminal Tripeptide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Fas C- Terminal Tripeptide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Fas C- Terminal Tripeptide

Fas C- Terminal Tripeptide,(C16H29N3O6), a tri-peptide with the sequence AC-SER-LEU-VAL-OH, it’s the C-terminal tripeptide of Fas, MW= 359.4. Fas (APO-1/CD95) is a cell surface receptor, which is a member of the tumor necrosis factor receptor (TNFR) superfamily, The Fas receptor is a death receptor on the surface of cells that leads to programmed cell death (apoptosis). It is one of two apoptosis pathways. Fas forms the death-inducing signaling complex (DISC) upon ligand binding. Upon ensuing death domain (DD) aggregation, the receptor complex is internalized via the cellular endosomal machinery. This allows the adaptor molecule FADD to bind the death domain of Fas through its own death domain. FADD also contains a death effector domain (DED) near its amino terminus,which facilitates binding to the DED of FADD-like interleukin-1 beta-converting enzyme (FLICE), more commonly referred to as caspase-8. FLICE can then self-activate through proteolytic cleavage into p10 and p18 subunits, two each of which form the active heterotetramer enzyme. Active caspase-8 is then released from the DISC into the cytosol, where it cleaves other effector caspases, eventually leading to DNA degradation, membrane blebbing, and other hallmarks of apoptosis.

The C-terminal tripeptide (AC-SER-LEU-VAL-OH) of Fas was necessary and sufficient both for binding to the third PDZ domain of FAP-1 and for inhibiting Fas/FAP-1 binding.

 BCC1019_1

Figure1  Formula of Fas C- Terminal Tripeptide

BCC1019_2

Figure2  Signaling pathway of Fas

Ref:

1. Lichter P, Walczak H, Weitz S, Behrmann I, Krammer PH (September 1992). "The human APO-1 (APT) antigen maps to 10q23, a region that is syntenic with mouse chromosome 19". Genomics 14 (1): 179–80.

2. Inazawa J, Itoh N, Abe T, Nagata S (November 1992). "Assignment of the human Fas antigen gene (Fas) to 10q24.1". Genomics 14 (3): 821–2.

3. Huang B, et al. (1996). "NMR structure and mutagenesis of the Fas (APO-1/CD95) death domain". Nature 384 (6610): 638–41.

4. Eberstadt M, et al. (1998). "NMR structure and mutagenesis of the FADD (Mort1) death-effector domain". Nature 392 (6679): 941–5.

Featured Products
New Products
 

References on Fas C- Terminal Tripeptide

Structural modification of Fas C-terminal tripeptide and its effects on the inhibitory activity of Fas/FAP-1 binding.[Pubmed:10464015]

J Med Chem. 1999 Aug 26;42(17):3289-99.

We report the structural requirements of the C-terminal tripeptide derivative of Fas (Ac-Ser-Leu-Val-OH, 1) for the inhibitory activity of Fas/FAP-1 binding. The presence of a carboxyl group and a L-Val residue at the C-terminus is essential for the inhibitory activity, and the hydroxyl group of Ser plays an important role as the donor of a hydrogen bond. The introduction of hydrophobic groups to the N-terminal region of 1, especially the phenylaminocarbonyl group (41), showed a remarkable increase in potency. Further improvement was observed by the attachment of the Glu residue to the meta-position of the phenyl ring of 41 (51). The ester derivative of 41 (56) had the ability to induce apoptosis which was dependent on the concentration of anti-Fas antibody in the colon cancer cell line, DLD-1, which expresses both Fas and FAP-1 and is resistant to Fas-induced apoptosis. We are now investigating whether FAP-1 is a main target of 56 and whether the inhibition of Fas/FAP-1 binding by 56 retrieves the apoptotic signal.

Keywords:

Fas C- Terminal Tripeptide,189109-90-8,Ac-Ser-Leu-Val-OH,Natural Products,Cancer Biology Peptides, buy Fas C- Terminal Tripeptide , Fas C- Terminal Tripeptide supplier , purchase Fas C- Terminal Tripeptide , Fas C- Terminal Tripeptide cost , Fas C- Terminal Tripeptide manufacturer , order Fas C- Terminal Tripeptide , high purity Fas C- Terminal Tripeptide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: